Verastem Prices $250M Offering at $8.00/Share — 30.9M Shares Plus Pre-Funded Warrants
VSTM has more than doubled off its 52-week low of $3.43 on elevated volume (12× avg).
Summary
Verastem priced a $250 million underwritten offering of 30.9 million shares at $8.00 per share plus pre-funded warrants, with net proceeds of approximately $234.7 million to fund VS-7375 clinical development.
Key Events · Financing and Capital Events · VSTM
-
$250M Offering Priced at $8.00/Share
30,937,500 shares at $8.00 plus 312,503 pre-funded warrants at $7.9999, totaling $249,999,992.75 in gross proceeds.
-
Net Proceeds of $234.7M
After $15.0M in underwriting discounts ($0.48/share) and $300K in expenses, net proceeds are approximately $234.7 million.
-
Priced Above Last Close
Offering price of $8.00 is above the October 13, 2026 last reported sale price of $7.45, indicating strong institutional demand following VS-7375 data.
-
Proceeds Fund VS-7375 Development
Net proceeds will fund continued clinical development of VS-7375, including the planned Phase 3 first-line pancreatic cancer trial, plus working capital.
Analysis · VSTM · Life Sciences
Verastem finalized the terms of its $250 million underwritten offering, pricing 30.9 million shares at $8.00 each plus 312,503 pre-funded warrants at $7.9999. The deal was priced at a premium to the October 13 closing price of $7.45, reflecting strong institutional demand following today's positive VS-7375 efficacy data. Net proceeds of approximately $234.7 million will fund the continued clinical development of VS-7375, including the planned Phase 3 first-line pancreatic cancer trial. The offering increases the share count by roughly 34% from the 90.5 million shares outstanding as of June 30, 2026, representing meaningful dilution to existing holders, though the capital meaningfully extends the company's cash runway.
How filings like this one have moved
In the 30 days to Oct 28, 2026, 38.5% of the 1020 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VSTM was trading at $7.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $698.2M. The 52-week trading range was $3.43 to $10.82. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.